MX2021006864A - Anticuerpos contra el factor c2b del complemento humano y metodos de uso. - Google Patents

Anticuerpos contra el factor c2b del complemento humano y metodos de uso.

Info

Publication number
MX2021006864A
MX2021006864A MX2021006864A MX2021006864A MX2021006864A MX 2021006864 A MX2021006864 A MX 2021006864A MX 2021006864 A MX2021006864 A MX 2021006864A MX 2021006864 A MX2021006864 A MX 2021006864A MX 2021006864 A MX2021006864 A MX 2021006864A
Authority
MX
Mexico
Prior art keywords
antibodies
antigen
binding fragments
human
methods
Prior art date
Application number
MX2021006864A
Other languages
English (en)
Inventor
Haard Hans De
Christophe Blanchetot
Original Assignee
Argenx Bvba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenx Bvba filed Critical Argenx Bvba
Publication of MX2021006864A publication Critical patent/MX2021006864A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan anticuerpos y fragmentos de unión a antígeno de los mismos que se unen específicamente al factor C2 del complemento humano y son capaces de inhibir la activación de la vía clásica y de las lectinas del sistema del complemento. Los anticuerpos y el fragmento de unión a antígeno exhiben una capacidad de preparación, una farmacocinética y un barrido de antígenos mejorada. También se proporcionan composiciones farmacéuticas que comprenden los anticuerpos y fragmentos de unión a antígeno, ácidos nucleicos y vectores que codifican los anticuerpos y fragmentos de unión a antígeno, células hospederas que comprenden los ácidos nucleicos o vectores, y métodos para preparar y usar los anticuerpos y fragmentos de unión a antígeno. Los anticuerpos y fragmentos de unión a antígeno se pueden usar para inhibir la vía clásica de activación del complemento en un sujeto, por ejemplo, un humano. Los anticuerpos y fragmentos de unión a antígeno también se pueden usar para inhibir la vía de las lectinas de activación del complemento en un sujeto, por ejemplo, un humano.
MX2021006864A 2018-12-13 2019-12-13 Anticuerpos contra el factor c2b del complemento humano y metodos de uso. MX2021006864A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862779102P 2018-12-13 2018-12-13
PCT/IB2019/060802 WO2020121282A1 (en) 2018-12-13 2019-12-13 Antibodies to human complement factor c2b and methods of use

Publications (1)

Publication Number Publication Date
MX2021006864A true MX2021006864A (es) 2021-07-02

Family

ID=69143627

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006864A MX2021006864A (es) 2018-12-13 2019-12-13 Anticuerpos contra el factor c2b del complemento humano y metodos de uso.

Country Status (13)

Country Link
US (4) US11161900B2 (es)
EP (2) EP4375297A2 (es)
JP (2) JP7110491B2 (es)
KR (1) KR20210100688A (es)
CN (1) CN113260375A (es)
AU (2) AU2019397614B2 (es)
BR (1) BR112021011107A2 (es)
CA (1) CA3119655A1 (es)
EA (1) EA202191658A1 (es)
IL (1) IL283916A (es)
MX (1) MX2021006864A (es)
SG (1) SG11202105195PA (es)
WO (1) WO2020121282A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020121282A1 (en) 2018-12-13 2020-06-18 Argenx Bvba Antibodies to human complement factor c2b and methods of use
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070818A1 (en) 2000-03-23 2001-09-27 Tanox, Inc. Anti-c2/c2a inhibitors of complement activation
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
US9399061B2 (en) 2006-04-10 2016-07-26 Abbvie Biotechnology Ltd Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis
KR101571027B1 (ko) * 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
PT3028716T (pt) 2006-10-10 2020-11-23 Regenesance B V Inibição do complemento para regeneração nervosa melhorada
KR101508086B1 (ko) * 2008-05-05 2015-04-07 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
WO2010056399A1 (en) 2008-11-17 2010-05-20 Incode Biopharmaceutics, Inc. Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors
CA2803588A1 (en) * 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the c3d fragment of complement component 3
KR101641057B1 (ko) * 2011-05-04 2016-07-20 오메로스 코포레이션 Masp-2 의존적 보체 활성화를 억제하는 조성물
WO2013036778A2 (en) 2011-09-07 2013-03-14 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved pharmacokinetic properties
WO2014096958A1 (en) 2012-11-02 2014-06-26 Academisch Medisch Centrum Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders
CA2889197A1 (en) * 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
EP2996722A4 (en) 2013-05-15 2017-01-11 Annexon, Inc. Methods of treatment for guillain-barre syndrome
DK2999714T3 (da) 2013-05-23 2020-06-02 Broteio Pharma B V Bindingsmolekyler som binder til human komplementfaktor C2 og anvendelser deraf
CA2859114A1 (en) 2013-08-29 2015-02-28 International Automotive Components Group North America, Inc. Formed articles comprising carbon and natural fibers, methods of manufacture and use thereof
AU2014329609B2 (en) * 2013-10-02 2019-09-12 Humabs Biomed Sa Neutralizing anti-influenza A antibodies and uses thereof
MX2016005017A (es) * 2013-10-17 2016-11-07 Omeros Corp Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
AU2014362262B2 (en) 2013-12-12 2021-05-13 Alnylam Pharmaceuticals, Inc. Complement component iRNA compositions and methods of use thereof
JP6951246B2 (ja) 2014-11-05 2021-10-20 アネクソン，インコーポレーテッド ヒト化抗補体因子Ｃ１ｑ抗体及びその使用
MX2018006249A (es) 2015-11-19 2018-11-09 Abbvie Stemcentrx Llc Nuevos anticuerpos anti-emr2 y metodos de uso.
SG11201803703UA (en) 2015-11-24 2018-06-28 Annexon Inc Anti-complement factor c1q fab fragments and uses thereof
EP3408291A1 (en) 2016-01-25 2018-12-05 Shire Human Genetic Therapies, Inc. Anti-c5 antibodies with enhanced ph switch
CA3012037A1 (en) 2016-01-27 2017-08-03 Csl Behring Recombinant Facility Ag Recombinant igg fc multimers
EP3454902A4 (en) 2016-05-10 2019-10-09 Annexon, Inc. ANTI-COMPLEMENT FACTOR C4 / C4B ANTIBODIES AND USES THEREOF
WO2018107109A1 (en) 2016-12-09 2018-06-14 Abbvie Stemcentrx Llc Novel anti-kremen2 antibodies and methods of use
BR112019018950A2 (pt) 2017-03-14 2020-04-22 Bioverativ Usa Inc métodos para tratamento de doenças e distúrbios mediados por complemento
MA50958A (fr) 2017-04-21 2020-10-14 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
EP3704252A1 (en) 2017-11-01 2020-09-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
WO2020121282A1 (en) 2018-12-13 2020-06-18 Argenx Bvba Antibodies to human complement factor c2b and methods of use

Also Published As

Publication number Publication date
US11161900B2 (en) 2021-11-02
EP4375297A2 (en) 2024-05-29
EP3893924A1 (en) 2021-10-20
CA3119655A1 (en) 2020-06-18
US11591386B2 (en) 2023-02-28
CN113260375A (zh) 2021-08-13
US20220119509A1 (en) 2022-04-21
US11708403B2 (en) 2023-07-25
EA202191658A1 (ru) 2021-11-03
US20220267424A1 (en) 2022-08-25
US20240002484A1 (en) 2024-01-04
SG11202105195PA (en) 2021-06-29
AU2019397614A1 (en) 2021-06-03
US20200239554A1 (en) 2020-07-30
KR20210100688A (ko) 2021-08-17
IL283916A (en) 2021-07-29
JP7110491B2 (ja) 2022-08-01
BR112021011107A2 (pt) 2021-12-14
JP2022512223A (ja) 2022-02-02
WO2020121282A1 (en) 2020-06-18
AU2019397614B2 (en) 2022-09-15
JP2022160479A (ja) 2022-10-19
AU2022287637A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
MX2022001222A (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos.
MX2020001996A (es) Moleculas anti-cd137 y uso de estas.
MX2022015901A (es) Proteinas de union biespecificas y usos de las mismas.
WO2018170338A3 (en) High affinity mage-a1-specific tcrs and uses thereof
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
ZA202100676B (en) Anti-tigit antibody and uses thereof
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
EA201891435A1 (ru) Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
PH12019502755A1 (en) Antibodies that specifically bind pd-1 and methods of use
EA202090275A2 (ru) Антитела против с5 с улучшенными фармакокинетическими характеристиками
PH12019500571A1 (en) Anti-pd-1 antibodies
WO2015108998A8 (en) Cartilage targeting agents and their use
MX351502B (es) Anticuerpos de union de albumina y fragmentos de union de los mismos.
EA201590138A1 (ru) Оптимизация антител, которые связывают ген активации лимфоцитов 3 (lag-3), и их применение
EA201892774A1 (ru) Антитела
MX2016002166A (es) Anticuerpos.
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
MX2021006864A (es) Anticuerpos contra el factor c2b del complemento humano y metodos de uso.
WO2016063026A3 (en) Selective nav protein binders
MX2017000171A (es) Anticuerpos biespecificos anti-il4-il13.
MX2018001964A (es) Polipeptidos mrka, anticuerpos y usos de los mismos.
WO2015057461A3 (en) Antibodies that specifically bind ataxia telangiectasia-mutated (atm) and rad3-related kinase phosphorylated
WO2016040767A3 (en) Chrdl-1 epitopes and antibodies